Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957414 | 0.83 | BAZ2B (0.42) | BAZ2BALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL15300166 | 0.83 | BAZ2B (0.42) | BAZ2BALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL5582059 | 0.83 | BAZ2B (0.46) | BAZ2BALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL4814588 | 0.79 | NPC1 (0.56) | ALDH1A1HPGDKDM4ENPC1RAB9A | |
| SCHEMBL10620933 | 0.74 | ALDH1A1 (0.58) | ALDH1A1HPGDKDM4ENPC1RAB9A | |
| SCHEMBL12597861 | 0.74 | CRBN (0.38) | ALDH1A1HPGDKDM4ENPC1RAB9A | |
| SCHEMBL5726927 | 0.74 | ALDH1A1 (0.34) | BAZ2BALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL11102779 | 0.73 | ALDH1A1 (0.36) | ALDH1A1HPGDKDM4ENPC1RAB9A | |
| SCHEMBL9288475 | 0.72 | ALDH1A1 (0.47) | BAZ2BALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL5727226 | 0.72 | PDE3B (0.38) | BAZ2BALDH1A1HPGDKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943224-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1943224-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| EP-1943224-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1943224-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007089291-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089291-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| EP-1680447-A2 | ORTHOGONAL GENE SWITCHES | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-07-19 | — | — | EP | disclosed |
| EP-1339683-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1339683-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005040212-A2 | ORTHOGONAL GENE SWITCHES | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2005-05-06 | — | — | WO | disclosed |
| EP-1339683-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002041835-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168188-A1 | Estrogen Receptor Modulators | ESR2, GPER1, ESRRA | BAZ2B 1608/4885ALDH1A1 1883/4885HPGD 809/4885 |
| US-20070087346-A1 | Orthogonal gene switches | TCF12, JUN, TCF7 | BAZ2B 219/4885ALDH1A1 3117/4885HPGD 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.